LIPOSYN III 10% Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Liposyn Iii 10%, and when can generic versions of Liposyn Iii 10% launch?
Liposyn Iii 10% is a drug marketed by Hospira and is included in one NDA.
The generic ingredient in LIPOSYN III 10% is soybean oil. There are thirteen drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the soybean oil profile page.
Summary for LIPOSYN III 10%
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Clinical Trials: | 4 |
Formulation / Manufacturing: | see details |
DailyMed Link: | LIPOSYN III 10% at DailyMed |
Recent Clinical Trials for LIPOSYN III 10%
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The Cleveland Clinic | Early Phase 1 |
Pennington Biomedical Research Center | Early Phase 1 |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | N/A |
Anatomical Therapeutic Chemical (ATC) Classes for LIPOSYN III 10%
US Patents and Regulatory Information for LIPOSYN III 10%
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospira | LIPOSYN III 10% | soybean oil | INJECTABLE;INJECTION | 018969-001 | Sep 24, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |